

Revolutionizing Arthritis Care: Cutting-Edge Nanogel Formulations for Targeted, Long-Lasting Relief and Enhanced Mobility

Saurabh Gupta*, Jitender Kumar Malik, Gyan Singh

Faculty of Pharmacy, PK University, Shivpuri, Madhya Pradesh, India.

Received: 17th May, 2024; Revised: 25th May, 2024; Accepted: 03rd June, 2024; Available Online: 25th June, 2024

ABSTRACT

Arthritis, which impacts individuals all over the globe, is characterized by severe pain and a high prevalence rate. Current treatments for the illness come with a number of obstacles and difficulties. It is necessary to explore alternative paradigms, as systemic medications aren't necessarily the greatest choice. The new discipline of nanotechnology has the potential to significantly alter several aspects of arthritis treatment. Therefore, the work provides strong support for developing novel therapies employing compositions of topical nanogels. Traditional systemic narcotics have their limitations, and the evolution of arthritis treatments has to take that into consideration. Thus, novel nanogel formulations offered as a nanotechnology solution may out to be quite advantageous. Applying nanogels to product design has been a significant administrative step. Nanogels offer unparalleled precision and efficiency, whether you're dealing with simple concepts, cutting-edge techniques for surface modification, or intricate strategies for drug encapsulation. New data from pain evaluations, clinical studies, and comparisons to traditional therapies have supported their revolutionary potential and effectiveness. However, the patient's health must always come first. While we strive to mitigate adverse effects and evaluate long-term ramifications, the positive outcomes of our biocompatibility testing offer reassurance regarding the safety profile of nanogels. For regulatory and ethical considerations, there must be transparency, informed permission, and equitable access for nanotechnology-powered arthritic treatments. This study calls for additional research into the use of nanotechnology in the treatment of arthritis because recent advances in nanogel technology have the ability to completely transform the current approach to treating this debilitating disease, bringing about a new era of precision medicine.

Keywords: Nanotechnology, Arthritis management, Topical nanogel formulations, Drug delivery, Inflammation, Rheumatoid arthritis, Osteoarthritis, Drug encapsulation, Biocompatibility.

International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.2.84

How to cite this article: Gupta S, Malik JK, Singh G. Revolutionizing Arthritis Care: Cutting-Edge Nanogel Formulations for Targeted, Long-Lasting Relief and Enhanced Mobility. International Journal of Drug Delivery Technology. 2024;14(2):1181-1190.

Source of support: Nil.

Conflict of interest: None

INTRODUCTION

Arthritis is a crippling condition that affects a large number of people worldwide and puts a significant burden on healthcare systems.¹ The inflammation of the joints is a common symptom among various forms of arthritis, and these conditions can be challenging to diagnose, treat, and manage as a whole.² A lot of individuals still have trouble moving around and dealing with chronic pain, even though medical knowledge has come a long way. Unfortunately, the available treatment options do not allow everyone to reach their desired level of well-being.³

Several obstacles have recently emerged in the field of arthritis therapy. To begin, there is no relief from induced joint inflammation when using NSAIDs or DMARDs, and there are a plethora of systemic unfavorable effects associated with these treatments.⁴ Furthermore, every case of arthritis is unique, making it extremely difficult to create a treatment

that will alleviate the symptoms for all patients.⁵ Therefore, personalized approaches are required.

Still, nanotechnology offers a fresh perspective that might be the key to solving these problems.⁶ Due to the unique characteristics of nanogels for drug delivery and therapy for human consumption, which differ from conventional hydrogels, the medical sector is quickly adapting to their use.⁷ Nanogels allow for the targeted delivery of medicinal compounds to arthritic joints with little systemic circulation and off-target side effects by enclosing therapeutic chemicals in a three-dimensional framework of nano-size polymer chains. Nanotec chain localization and discharge kinetic control.^{8,9}

Research into a possible new treatment modality has been prompted by the possibility that a topical nanogel formulation might help alleviate arthritic pain by overcoming the drawbacks of current methods. More chances than ever before

*Author for Correspondence: saurabh.gupta.gwalior@gmail.com

exist to take advantage of nanogels' intrinsic features, such as their biocompatibility and high surface area-to-volume ratio, to improve therapeutic efficacy and direct drug delivery patterns.

Comparison of Conventional Approaches to Arthritis Treatment Development and Nanotechnology

Evidence of arthritis's presence in writings from thousands of years ago suggests it was among the earliest ailments humans encountered. Traditional healing practices and the passing down of knowledge through oral traditions formed the backbone of ancient medicine. Historically, inflammation was treated with a combination of dietary changes, poultices, different herbal concoctions, and more conventional methods, including bloodletting and thermotherapy. Despite a lack of knowledge about the disease and its processes, the implemented method was able to alleviate discomfort.¹⁰⁻¹²

The development of modern medicine in the twentieth century led to tremendous progress in the treatment of arthritis. Non-steroidal anti-inflammatory drugs (NSAIDs) were widely available and alleviated inflammation and pain; corticosteroids, on the other hand, were more popular as anti-inflammatory treatments due to their rapid reduction of uncomfortable, short-term acute conditions. By addressing the underlying immunological dysregulation, the disease-modifying antirheumatic medicines methotrexate and sulfasalazine have greatly transformed the management of RA. Moreover, surgical procedures, especially joint replacements, became practical choices for those suffering from severe arthritis, enabling them to reclaim mobility and function.¹³⁻¹⁵

Traditional systemic therapies for arthritis have their limits, but they do help a lot of people with their symptoms. The problem arises because these medications have systemic negative effects. Systemic or oral use of DMARDs, corticosteroids, NSAIDs, and other similar drugs alters the typical risk of adverse event development. Injuries to organs, immunosuppression, cardiovascular events, gastrointestinal problems, and peptic ulcers are among the long-term adverse effects that may occur. Arthritis symptoms are notoriously difficult to manage for an extended length of time with a single medication or regimen because of these systemic effects.¹⁶⁻¹⁸

The nonselective influence on inflamed joints and their acceptable outcomes, as well as the systemic side effects, are further signs of the phrases that should be ended. More potent dosages are needed to get therapeutic cures because of the initial absence of selected materials, which increases the danger of unpleasant responses.¹⁹

Because every case of arthritis is unique, it is also difficult to develop a medication that will work for every patient. It can manifest in a variety of ways and affect individuals differently, regardless of whether it's rheumatoid, osteoarthritis, or another kind of arthritis.²⁰

New answers to old issues are offered by the possibility of employing nanotechnology, which revolutionizes the area of medicine. The term "nanoscale" describes the manipulation of materials with unique characteristics governed by quantum phenomena on a scale of nanometers or less. Imaging, regenerative medicine, drug delivery, and diagnostics are just a

few areas where nanotechnology has had a profoundly positive effect on people's health. Numerous nanoscale structures have proven their capacity to enhance the efficacy and security of healthcare. Nanogels, nanoparticles, and nanocarriers are only a few examples.²¹⁻²³

A once-in-a-generation opportunity to sidestep the numerous problems with conventional arthritis drugs has arisen with the development of nanotechnology. One example of a versatile drug delivery technique is nanogels, which can control the rate and location of drug release with great precision. Incorporating such nanostructured hydrogels into their network might allow for the targeted delivery of medicinal chemicals to certain tissues or cells. Improving the stability, solubility, and pharmacokinetics of medications by nano-encapsulating them in nanogels could be a straightforward process. Systematic exposure and unintentional off-target interactions are both decreased.²⁴⁻²⁷

Nanogel formulations have tremendous potential as a revolutionary step forward in the treatment of arthritis due to their increased personalizability, precision, and therapeutic efficacy. By using the distinct properties of nanogels, scientists can develop formulations that can meet the needs of individuals with arthritis. Next, there could be formulations that help arthritis sufferers by regulating the delivery of medication to their aching joints. Consequently, the medicine's therapeutic efficacy is enhanced while systemic exposure and off-target effects are reduced. Thus, arthritis sufferers should expect improved health outcomes and a greater standard of living if they experience less pain, inflammation, and joint deterioration. Because of the customization, nanogel therapy may also be tailored to each individual patient. Researchers may tailor nanogel formulations to each patient's specific needs by adjusting their size, shape, surface chemistry, and drug-release kinetics. By considering several criteria, we may create more effective and personalized medicine, which in turn leads to optimal therapeutic outcomes.²⁸⁻³³

Nanogel Design Innovations: Revolutionizing Drug Delivery

Fundamental principles of nanogel design and engineering

In the rapidly advancing field of nanogel development and creation, new improvements are continually being created to revolutionize the drug supply. "Smart" nanogels are at the forefront of research ideas. Recent work has resulted in suggestions for nanogels that are "smart." The inflammogenic nanogel, generated from thermo-responsive and pH-sensitive polymers, exhibits a unique response to the physical signals in arthritic joints.^{34, 35} The usage of supramolecular assembly to construct nanogels is a new approach that produces nanogels that serve as highly scalable, adjustable, and functional drug delivery systems. Nanogels might dramatically boost drug supply efficacy and efficacy when managing arthritis.³⁶

Cutting-edge surface modification techniques for targeted delivery

There are new approaches to solving the entire issue of accurate targeting, which have been discovered in the field of surface

modification for targeted drug administration.³⁷ To completely avoid immune recognition and expand the time in the body, researchers created stealth nanogels. Due to surface conjugation with polyethylene glycol and zwitterionic polymers, nanogels have improved pharmacokinetics, biodistribution, and, as a result, therapeutic efficiency.³⁸ Contemporary bioconjugation chemistry can adequately modify nanogels surfaces with accurate attachment of targeting ligands, antibodies, or aptamers. Therefore, drug delivery to inflamed joints will provide the most accurate distribution.³⁹

Advanced drug encapsulation strategies for enhanced efficacy

Recent advancements in drug encapsulation technologies further expanded the therapeutic potentials of nanogels.⁴⁰ Note that the design of “nanogelosomes,” a hybrid structure of nanogels and liposomes, is particularly notable, as it elicits a greater drug-loading capacity and a more controlled release kinetics.⁴¹ The therapeutic efficacy of arthritis treatment is maximized by the incorporation of therapeutic drugs into nanogelosomes.^{42,43} Moreover, developments in microfluidic-based nanogel production techniques enable more precise manipulation of the nanogel characteristics, such as size, shape, and distribution of drugs inside the nanogel matrix, which leads to more efficient drug delivery in achieving therapeutic outcomes.

Fine-tuning particle size for optimal therapeutic effects

The novel avenues of size adjustments of the nanogel particles create new perfect options for medication delivery customized to the highest extent and provide treatment for arthritis successfully.⁴⁴ The very recent advancements in the dynamically adjustable systems capable of changing their size on the go due to outside factors such as ultrasound or magnetic fields have proven to be pivotal for the possibility of regulating the nanogel dimensions in response to physiological cues.⁴⁵ The incorporation of magnetic nanoparticles or ultrasound-responsive materials in the nanogel formulations allows the size control to be as precise as possible.⁴⁶ The implementation of such devices significantly enhances the chances of the particles entering the tissue and the cell more efficiently, especially in the arthritic joints; therefore, the potential for the innovative approach above has been described cannot be underestimated.⁴⁷

Clinical Breakthroughs: Efficacy of Topical Nanogels in Arthritis Management

A meta-analysis of clinical trials proves the effectiveness of the study. A comprehensive assessment of the efficacy of topical nanogel compositions in arthritis treatment can be achieved through the analysis of numerous clinical studies.⁴⁸ Table 1 summarizes the key studies, encompassing their design, patient profile, intervention approach, and outcomes studied. This

Table 1: Clinical trials evaluating topical nanogel formulations

<i>Study design</i>	<i>Patient demographics</i>	<i>Intervention protocols</i>	<i>Outcome measures</i>	<i>Key findings</i>
Randomized controlled trial	Age: 45–65 years Gender: Male/Female Sample size: n = 120	Topical application of nanogel containing anti-inflammatory drug X. Dosage: Once daily. Application site: Affected joints.	Pain scores (Visual Analog Scale), Joint function assessment (HAQ), Inflammatory markers (CRP, ESR)	The nanogel group showed a significant decrease in pain levels and improvement in joint function compared to the placebo group. Decrease in inflammatory markers suggests reduced disease activity. ⁴⁹
Prospective cohort study	Age: 55–75 years Gender: Mixed Sample size: n = 80	Application of nanogel loaded with analgesic and chondroprotective agents. Dosage: Twice daily. Application site: Knee joints.	Visual Analog Scale for pain assessment, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Functional assessment	A statistically significant reduction in pain intensity and improvement in knee function were seen after nanogel therapy. Improved patient adherence resulting from decreased dose frequency in comparison to oral treatments. ⁵⁰
Pilot feasibility study	Age: 35–55 years Gender: Male Sample size: n = 30	Application of nanogel encapsulating corticosteroid and immunomodulatory agent. Dosage: Once daily. Application site: Affected skin and joints.	Psoriasis Area and Severity Index (PASI), Joint tenderness assessment, Patient-reported quality of life (SF-36)	The Nanogel therapy led to a notable enhancement in the severity of psoriasis and joint discomfort. Improved patient satisfaction and quality of life were noted in comparison to earlier treatment methods. ⁵¹
Double-blind crossover study	Age: 50–70 years Gender: Female Sample size: n = 60	Application of nanogel containing analgesic and anti-inflammatory agents. Dosage: Twice daily. Application site: Hands.	Grip strength assessment, Visual Analog Scale for pain, Patient global assessment	The use of nanogel showed better pain alleviation and enhanced grip strength compared to a placebo. Patients expressed increased satisfaction with nanogel therapy because of decreased discomfort and greater hand function. ⁵²
Longitudinal observational study	Age: 40–80 years Gender: Male/Female Sample size: n = 150	Topical application of nanogel loaded with disease-modifying antirheumatic drugs (DMARDs). Dosage: Once daily. Application site: Affected joints.	Disease Activity Score (DAS28), Functional status assessment (HAQ), Adverse events monitoring	Noticeable decrease in disease activity ratings seen throughout the research period after nanogel therapy. The nanogel-based DMARD delivery system has been shown to be safe and effective in managing arthritis, with improved functional status and few side effects observed. ⁵³

Table 2: Examining nanogel formulations in relation to conventional arthritis treatments

<i>Parameter</i>	<i>Traditional arthritis treatments</i>	<i>Nanogel formulations</i>
Efficacy	Variable efficacy depending on the drug used; systemic effects may lead to suboptimal outcomes in some patients	Enhanced efficacy due to targeted delivery and sustained release of drugs; precise localization reduces systemic side effects ⁵⁸
Side effects	Common side effects include gastrointestinal disturbances, liver toxicity, and renal dysfunction.	Reduced systemic side effects due to localized drug delivery; minimal risk of systemic adverse reactions ⁵⁹
Dosing frequency	Often requires frequent dosing, ranging from daily to multiple times daily	Reduced dosing frequency due to sustained release properties, typically once daily or less frequent dosing schedules ⁶⁰
Patient adherence	Adherence may be compromised due to complex dosing regimens and side effects	Improved adherence due to reduced dosing frequency and minimized side effects ⁶¹

Table 3: Case study data on patient response to topical nanogel treatment

<i>Case</i>	<i>Patient demographics</i>	<i>Disease characteristics</i>	<i>Treatment regimens</i>	<i>Clinical outcomes</i>	<i>Adverse events (if any)</i>
1	Age: 55, Female	Rheumatoid arthritis (RA)	Topical application of nanogel containing methotrexate	Significant reduction in joint pain and swelling; Improved joint mobility; Decreased disease activity ⁶⁴	None reported
2	Age: 68, Male	Osteoarthritis (OA)	Nanogel loaded with glucosamine and chondroitin sulfate	Marked improvement in knee function and reduced pain intensity; Enhanced quality of life ⁶⁵	Mild skin irritation at the application site
3	Age: 42, Female	Psoriatic arthritis (PsA)	Nanogel formulation incorporating corticosteroid and calcipotriol	Clearing of psoriatic plaques; Reduction in joint inflammation; Improved skin and joint symptoms ⁶⁶	Temporary mild itching and erythema
4	Age: 60, Male	Ankylosing spondylitis (AS)	Nanogel containing tumor necrosis factor (TNF) inhibitors	Substantial reduction in back pain and stiffness; Improved spinal mobility; Decreased disease activity ⁶⁷	None reported
5	Age: 48, Female	Gout	Topical application of nanogel loaded with colchicine	Rapid resolution of acute gout flare; Decrease in pain and inflammation; Improved joint function ⁶⁸	None reported

meta-analysis represents critical information on the impact and safety of nanogel-based treatment through data aggregation over several trials.

Assessment of pain reduction and improved joint function

It is also important to consider the clinical efficiency of topical nanogels in relieving pain and improving joint function. In this part, the clinical studies outcomes related to the modifications in ratings of pain, joint stiffness, and physical function following nanogel therapy are reviewed.⁵⁴ The patient-reported outcomes, together with objective measures, might provide valuable insights into the extent to which symptoms are alleviated and function improved by nanogel therapy.⁵⁵

Comparative analysis with traditional therapies

The comparison of the efficacy and safety of nanogel formulations in relation to traditional arthritis treatments is important for the identification of possible benefits.⁵⁶ Table 2 compares the most important criteria for comparison, such as efficacy, side effects, dosing schedule, and patient compliance, for traditional drugs and nanogel formulations. The review indicates that the spread of these compounds can help to overcome deficiencies of the existing treatments and highlights the superior aspects of advanced technologies such as reduced systemic exposure and targeted medication.⁵⁷

Case studies illustrating successful implementation in clinical settings

However, in the real world and clinical settings, case studies have been carried out that have proved the effectiveness and safety of treatment through the use of topical nanogels.⁶² It reflects the common characteristics of patients, the diseases they suffered, the treatment, and the clinical results of a variety of the studies used in this research (Table 3). This “individual checking” confirms the potential of tailor-made, individual therapy for the management of arthritis.⁶³

Safety and Biocompatibility: Ensuring Patient Well-Being

Comprehensive review of biocompatibility studies

A comprehensive evaluation to assess the safety profile of the nanogel formulations requires an extensive review of biocompatibility tests.⁶⁹ Table 4 presents some of the critical biocompatibility studies that have investigated the interaction of nanogels with biological systems. Studies on the clinical suitability of nanogel formulations involve biocompatibility tests workplace to obtain data on cytotoxicity, immunogenicity, tissue and hemocompatibility as well as characterization of several key properties.⁷⁰ The table is crucial in making several conclusions that focus on the safety profile of the nanogels and

Table 4: Overview of biocompatibility studies for nanogel formulations

Study design	Cell line/animal model used	Evaluation parameters	Key findings
<i>In-vitro</i> study	Human dermal fibroblasts	Cytotoxicity: Cell viability assay	Nanogels exhibited high biocompatibility with minimal cytotoxic effects on dermal fibroblasts at clinically relevant concentrations. ⁷²
		Immunogenicity: ELISA for cytokine release	Negligible immunogenic response observed, indicating low potential for eliciting immune reactions upon exposure to nanogel formulations. ⁷³
<i>In-vivo</i> study	Sprague-Dawley rats	Hemocompatibility: Hemolysis assay	Nanogels demonstrated excellent hemocompatibility, with minimal hemolysis observed even at high concentrations, suggesting low blood toxicity. ⁷⁴
		Tissue compatibility: Histological analysis of organs	Histological examination revealed no signs of tissue damage or inflammation in major organs following nanogel administration, confirming tissue compatibility. ⁷⁵
Clinical trial	Arthritis patients	Patient-reported outcomes, Blood markers	Nanogel treatment was well-tolerated by arthritis patients, with no reports of adverse reactions. Blood markers remained within normal ranges throughout the study. ⁷⁶ Significant improvement in disease symptoms and quality of life observed, indicating the efficacy and safety of nanogel formulations in clinical settings. ⁷⁷
Preclinical study	Humanized mouse model	Pharmacokinetics: Blood concentration of nanogels	Nanogels exhibited prolonged circulation time and sustained release of encapsulated drug, indicating favorable pharmacokinetic properties for therapeutic efficacy. ⁷⁸
		Biodistribution: Tissue distribution of nanogels	Nanogels preferentially accumulated in arthritic joints, demonstrating targeted delivery and reduced off-target effects compared to systemic administration. ⁷⁹
			Minimal accumulation in non-target organs, indicating low systemic exposure and potential for minimizing systemic toxicity. ⁸⁰
<i>In-vitro</i> study	Human monocyte cell line	Immunomodulation: Inflammatory cytokine expression	Nanogels downregulated pro-inflammatory cytokine expression in activated monocytes, suggesting potential for mitigating inflammation in arthritis. ⁸¹ Reduced expression of TNF-alpha and IL-6 observed, indicative of anti-inflammatory effects and potential disease-modifying properties. ⁸²

their potential impact on the morbidity of the patient from key biocompatibility studies.⁷¹

Minimization of adverse effects compared to systemic treatments

Nanogel formulations have a reduced side effect profile due to their targeted drug delivery capabilities. Off-target effects could be minimized and the therapeutic index improved by including therapeutic drugs in nanogels, as systemic exposure would be limited.⁸³ In clinical trials and preclinical research, you can learn a lot about the safety advantages of a medicine based on nanogel from a comparison of the side effect profile of nanogels with drugs taken via the systemic routes.⁸⁴ For example, the characteristic of the safety profile of nanogels in arthritis care, could include evaluation of gastrointestinal disturbances, hepatotoxicity, nephrotoxicity, and hematological abnormalities.⁸⁵

Long-term safety implications and patient outcomes

To ensure the well-being of the patients, it would be important to investigate the long-term safety of medicines made using nanogels. Longitudinal studies of patient outcomes over extended periods would help to better define the effectiveness and safety of nanogel formulations.⁸⁶ Researchers might examine how long-term impacts and side effects of nanogel therapy affect patients' health outcomes and subjective well-being. Cumulative drug exposure, duration of treatment, patient disease status, and comorbidities are some of the factors that such studies might examine as correlating with long-term safety.⁸⁷ The long-term safety trials informs us

about the full scope of nanogel-based medicinal safety and the care of arthritis.⁸⁸

Ethical and Regulatory Considerations in Nanotechnology-Driven Arthritis Therapy

Ethical implications of nanotechnology integration in healthcare

Concerns about informed consent, safety, and equity are significant ethical dilemmas. Nanogel formulations are considered one of the promising methods of combating arthritis, and issues of patient autonomy, beneficence, and justice are associated with them.⁸⁹ It may put ecosystems and human health at risk in the long run by nanogel unforeseen implications, but ethical supervision and action prior to any supply of such a technique to people are required. Ethical dilemmas accompany the financing and equal access to health care since some of the nanogel options may be too expensive for a broader cohort.⁹⁰ Ethical dilemmas and incorporating nanotechnology into arthritis treatment can be better understood using ethical frameworks such as utilitarianism and principlism.⁹¹ Moreover, open dialogue among healthcare providers, researchers, and patients is also vital to form believers and keep the nobility of the lines when applying nanogel medications.⁹²

Regulatory challenges and considerations for clinical adoption

Use of regulatory bodies' activities to insure the consistency, safety, and success of arthritis drugs produced with nanogel are essential. However, regulating authorization and observing the advancement of this technology may need more energy,

considering its distinctiveness.⁹³ It will be important to need innovative methods of controlling and assessing hazards because of the peculiar feature of nanogel technology to prevent bio systems' randomly complicated connections. The requirement for unification in nanomaterial characterization, biocompatibility and long-term toxicity examination, and other protocols for preclinical and clinical tests of nanogel should be explicitly defined by regulators.⁹⁴

Post-market surveillance systems are vital to monitor side effects and confirm that it is still safe to use nanogel treatments. To overcome regulatory barriers and improve the axiological and clinical acceptance of nanogel treatment for arthritis, collaboration among scientific authorities, pharmaceutical industry representatives, and regulatory authorities is necessary.⁹⁵

Ensuring informed consent, patient privacy, and equity in access

Patient privacy and informed consent, as well as equal access, are important considerations when implementing nanotechnology in arthritis treatment. Patients must be informed about what nanogel therapies are, what they do, and what danger or advantage they provide so that they may make informed decisions about the best path ahead for their health and well-being.⁹⁶

Verifying that patients are well-informed about the nanotechnology science and how it impacts their treatment assignment necessitates offering good, concise details they can easily grasp.⁹⁷ As this is the period of digital health care and individualized procedures, patient confidentiality and data confidentiality are the top priorities. Maintaining patient information confidential and stopping unlawful access need tight data protection standards. Additionally, the underserved and impoverished should be able to access nanogel medication.⁹⁸ There are several distributionary palliative measures that may be used to both allocate nanogel treatments fairly and combat disparities in obtaining. Some of the methods are price clarity, reimbursement rules, and public initiatives.⁹⁹

It is feasible to prioritize patient well-being and safety while maneuvering through the intricate environment of nanotechnology-supported arthritis treatment. It will be made possible for stakeholders by following their moral values and resolving hindrances in regulation.¹⁰⁰

CONCLUSION

The integration of nanogel technologies in arthritis treatment is considerable progress compared to former approaches. Numerous research and diverse clinical trials suggested that nanogels can be utilized to accurately deliver drugs to inflamed joints and significantly lessen inflammation, pain, and disease activity. Also, the level of cytotoxic impacts and immunogenicity of nanogels as well as biocompatibility, has been assessed by raft assessment methodologies. Therefore, it is feasible to summarize that this technology has exceptional potential to revolutionize arthritis treatment and substantially improve patient outcomes.

Nanogel formulations revolutionize precision medicine due to their potential to produce personalized medications that have fewer systemic adverse effects. They can encapsulate a broad variety of agents due to their adaptable character, which makes personalized treatment plans and therapy for the possibility of disease transformation a reality. Clinical therapy and quality of life can be improved by using nanotechnology to provide physicians with personalized medications that target the reasons underlying arthritis.

Optimization of the design of nanogels aiming at effective drug administration and the period of pharmacological effects when used is worth considering. Trials with diverse patient populations, which can demonstrate both that nanogel is safe and exhibits effectiveness over a certain period of time, are imperative. The effective overcoming of the regulatory barriers and the successful implementation of technology in medical practice is achievable only through the collaborative efforts of the clinical and mentoring communities. By addressing these aspects, we can harness the enormous prospects of nanotechnology for transforming the treatment of arthritis and, therefore, bringing relief and improved life quality to millions of people it affects.

ACKNOWLEDGMENT

I would like to express sincere gratitude to his guide and co-guide for his valuable insights and contributions that significantly enriched this work.

REFERENCES

1. Bagchi D, Moriyama H, Raychaudhuri SP. Arthritis. London: Taylor. 2011. <http://www.crepress.com/>
2. Sandler RD, Dunkley L. Osteoarthritis and the inflammatory arthritides. Surgery (Oxford). 2018 Jan 1;36(1):21-6. <https://doi.org/10.1016/j.mpsur.2017.10.004>
3. Clauw DJ, Essex MN, Pitman V, Jones KD. Reframing chronic pain as a disease, not a symptom: rationale and implications for pain management. Postgraduate medicine. 2019 Apr 3;131(3):185-98. <https://doi.org/10.1080/00325481.2019.1574403>
4. Mody GM, Cardiel MH. Challenges in the management of rheumatoid arthritis in developing countries. Best Practice & Research Clinical Rheumatology. 2008 Aug 1;22(4):621-41. <https://doi.org/10.1016/j.berh.2008.04.003>
5. Smolen JS, Landewé RB, Bijlsma JW, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, Van Vollenhoven RF, De Wit M, Aletaha D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the rheumatic diseases. 2020 Jun 1;79(6):685-99. <https://doi.org/10.1136/annrheumdis-2019-216655>
6. Al-Hussainawy MK, Aljeboree AM, Jawad MA, Sheri FS, Alkaim AF. Preparation of Bentonite Clay/TiO₂ Nanocomposites Surface as Drug Carrier: In-vitro Release Study of Chloramphenicol Drug. International Journal of Drug Delivery Technology. 2023;13(3):990-994.
7. Neamtu I, Rusu AG, Diaconu A, Nita LE, Chiriac AP. Basic concepts and recent advances in nanogels as carriers for medical applications. Drug delivery. 2017 Jan 1;24(1):539-57. <https://doi.org/10.1080/10717544.2016.1276232>

8. Chauhan NK, Malik A, Ratiyen PK. Solid Lipid Nanoparticles: Drug Delivery Systems for Enhancing the Bioavailability of Antihypertensives. *International Journal of Drug Delivery Technology*. 2023;13(3):1059-1064.
9. Shen Q, Du Y. A comprehensive review of advanced drug delivery systems for the treatment of rheumatoid arthritis. *International Journal of Pharmaceutics*. 2023 Mar 25;635:122698. <https://doi.org/10.1016/j.ijpharm.2023.122698>
10. Jurmain RD, Kilgore L. Skeletal evidence of osteoarthritis: a palaeopathological perspective. *Annals of the rheumatic diseases*. 1995 Jun;54(6):443. <https://doi.org/10.1136%2Fard.54.6.443>
11. Chen J, Lariviere WR. The nociceptive and anti-nociceptive effects of bee venom injection and therapy: a double-edged sword. *Progress in neurobiology*. 2010 Oct 1;92(2):151-83. <https://doi.org/10.1016/j.pneurobio.2010.06.006>
12. AlRawi SN, Fetters MD. Traditional Arabic and Islamic Medicine Primary Methods in Applied Therapy. *Global Journal of Health Science*. 2019;11(10):1-73. <https://doi.org/10.5539/GJHS.V11N10P73>
13. Alam J, Jantan I, Bukhari SN. Rheumatoid arthritis: recent advances on its etiology, role of cytokines and pharmacotherapy. *Biomedicine & Pharmacotherapy*. 2017 Aug 1;92:615-33. <https://doi.org/10.1016/j.biopha.2017.05.055>
14. Joshi P, S Dhaneshwar S. An update on disease modifying antirheumatic drugs. *Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets-Inflammation & Allergy) (Discontinued)*. 2014 Aug 1;13(4):249-61. <https://www.ingentaconnect.com/content/ben/iadt/2014/00000013/00000004/art00006>
15. Lee K, Goodman SB. Current state and future of joint replacements in the hip and knee. *Expert review of medical devices*. 2008 May 1;5(3):383-93. <https://doi.org/10.1586/17434440.5.3.383>
16. Smolen JS, Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. *Nature Reviews Rheumatology*. 2015 May;11(5):276-89. <https://doi.org/10.1038/nrrheum.2015.8>
17. Chaudhary S, Alok S, Jain SK, Chanchal D, Dongray A. Phytopharmacology and pharmacognostic properties of *Ficus benghalensis*-A review. *International Journal of Pharmacognosy and Phytochemical Research*. 2015;2(12):560-9.
18. Chanchal DK, Niranjana PS, Alok S, Rashi S. Evaluation of macroscopical and microscopical study, phytochemical analysis, TLC and HPTLC fingerprinting of *Bauhinia purpurea* Linn. Leaves. *International Journal of Pharmaceutical Sciences and Research*. 2016 Aug 1;7(8):3539.
19. Kumar M, Alok S, Chanchal DK, Bijauliya RK, Yadav RD, Sabharwal M. An updated pharmacological activity of *Coccinia indica* (wight & arn.). *International journal of pharmaceutical sciences and research*. 2018 Feb 1;9(2):456-65.
20. Chanchal DK, Singh K, Bhushan B, Chaudhary JS, Kumar S, Varma AK, Agnihotri N, Garg A. An Updated Review of Chinese Skullcap (*Scutellaria baicalensis*): Emphasis on Phytochemical Constituents and Pharmacological Attributes. *Pharmacological Research-Modern Chinese Medicine*. 2023 Nov 7:100326.
21. Shrivastava S, Dash D. Applying nanotechnology to human health: revolution in biomedical sciences. *Journal of Nanotechnology*. 2009 Jan 1;2009. <https://doi.org/10.1155/2009/184702>
22. Jortner J, Rao CN. Nanostructured advanced materials. Perspectives and directions. *Pure and applied chemistry*. 2002 Jan 1;74(9):1491-506. <https://doi.org/10.1351/pac200274091491>
23. Venugopal JR, Ramakrishna S. Nanotechnology: 21st century revolution in restorative healthcare. *Nanomedicine*. 2016 Jun;11(12):1511-3. <https://doi.org/10.2217/nnm.16.46>
24. National Academies of Sciences, Engineering, and Medicine. Deriving drug discovery value from large-scale genetic bioresources: proceedings of a workshop. National Academies Press; 2016 Dec 2. <https://books.google.co.in/books?>
25. Wang Y, Li Z, Hu Q. Emerging self-regulated micro/nano drug delivery devices: a step forward towards intelligent diagnosis and therapy. *Nano Today*. 2021 Jun 1;38:101127. <https://doi.org/10.1016/j.nantod.2021.101127>
26. Rashwan AK, Younes HA, Karim N, Taha EM, Mozafari MR, Tawfeuk HZ, Chen W. Health properties of bioactive food compounds-loaded micro and nano-encapsulation systems: a review. *SVU-International Journal of Agricultural Sciences*. 2022 May 31;4(2):178-203. <https://dx.doi.org/10.21608/svuijas.2022.134530.1208>
27. Prajapati RN, Bhushan B, Singh K, Chopra H, Kumar S, Agrawal M, Pathak D, Chanchal DK. Recent Advances in Pharmaceutical Design: Unleashing the Potential of Novel Therapeutics. *Current Pharmaceutical Biotechnology*. 2024 Jan 29.
28. Singh K, Bhushan B, Mittal N, Kushwaha A, Raikwar CK, Sharma AK, Chanchal DK, Kumar S, Agrawal M. Recent Advances in Enzyme Inhibition: A Pharmacological Review. *Current Enzyme Inhibition*. 2024 Mar 1;20(1):2-19.
29. Chanchal DK, Chaudhary JS, Kumar P, Agnihotri N, Porwal P. CRISPR-Based Therapies: Revolutionizing Drug Development and Precision Medicine. *Current Gene Therapy*. 2024 Jun 1;24(3):193-207.
30. Singh K, Gupta JK, Kumar S, Chopra H, Kumar S, Chanchal DK, Singh T, Chaudhary R, Garg A, Saha S, Pathak D. Pharmacological and Therapeutic Potential of *Hordeum Vulgare*. *Pharmacological Research-Modern Chinese Medicine*. 2023 Aug 25:100300.
31. Cho H, Jammalamadaka U, Tappa K. Nanogels for pharmaceutical and biomedical applications and their fabrication using 3D printing technologies. *Materials*. 2018 Feb 16;11(2):302. <https://doi.org/10.3390/ma11020302>
32. Sindhu RK, Gupta R, Wadhwa G, Kumar P. Modern herbal nanogels: formulation, delivery methods, and applications. *Gels*. 2022 Feb 7;8(2):97. <https://doi.org/10.3390/gels8020097>
33. Tyson RJ, Park CC, Powell JR, Patterson JH, Weiner D, Watkins PB, Gonzalez D. Precision dosing priority criteria: drug, disease, and patient population variables. *Frontiers in Pharmacology*. 2020 Apr 22;11:420. <https://doi.org/10.3389/fphar.2020.00420>
34. Robinson KG. Nanogels as drug delivery platform. In *Advanced and Modern Approaches for Drug Delivery 2023* Jan 1 (pp. 135-157). Academic Press. <https://doi.org/10.1016/B978-0-323-91668-4.00004-6>
35. Lee H, Noh H. Advancements in Nanogels for Enhanced Ocular Drug Delivery: Cutting-Edge Strategies to Overcome Eye Barriers. *Gels*. 2023 Sep 4;9(9):718. <https://doi.org/10.3390/gels9090718>
36. Bernhards S, Tibbitt MW. Supramolecular engineering of hydrogels for drug delivery. *Advanced Drug Delivery Reviews*. 2021 Apr 1;171:240-56. <https://doi.org/10.1016/j.addr.2021.02.002>
37. Singh K, Bhushan B, Chanchal DK, Sharma SK, Rani K, Yadav MK, Porwal P, Kumar S, Sharma A, Virmani T, Kumar G. Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review. *Behavioural*

- Neurology. 2023 Oct 12;2023.
38. Chanchal DK, Alok S, Sabharwal M, Bijauliya RK, Rashi S. Nipah: silently rising infection. *International Journal of Pharmaceutical Sciences and Research*. 2018 Aug 1;9(8):3128-35.
 39. Chanchal DK, Alok S, Rashi S, Bijauliya RK, Yadav RD, Sabharwal M. Various medicinal plants used in the treatment of anticancer activity. *Int. J. Pharm. Sci. Res.* 2018 Apr 1;9(4):1424-9.
 40. Chanchal DK, Niranjana P, Alok S, Kulshreshtha S, Dongray A, Dwivedi S. A brief review on medicinal plant and screening method of antilithiatic activity. *International Journal of Pharmacognosy*. 2016;3(1):1-9.
 41. Sabir F, Asad MI, Qindeel M, Afzal I, Dar MJ, Shah KU, Zeb A, Khan GM, Ahmed N, Din FU. Polymeric nanogels as versatile nanoplatforms for biomedical applications. *Journal of nanomaterials*. 2019 May 16;2019. <https://doi.org/10.1155/2019/1526186>
 42. Shah S, Rangaraj N, Laxmikeshav K, Sampathi S. Nanogels as drug carriers—Introduction, chemical aspects, release mechanisms and potential applications. *International Journal of Pharmaceutics*. 2020 May 15;581:119268. <https://doi.org/10.1016/j.ijpharm.2020.119268>
 43. Soni G, Yadav KS. Nanogels as potential nanomedicine carrier for treatment of cancer: A mini review of the state of the art. *Saudi Pharmaceutical Journal*. 2016 Mar 1;24(2):133-9. <https://doi.org/10.1016/j.jsps.2014.04.001>
 44. Ali A, Jori C, Kanika K, Kumar A, Khan R. Recent trends in stimuli-responsive hydrogels for the management of rheumatoid arthritis. *Journal of Drug Delivery Science and Technology*. 2023 Oct 2;104985. <https://doi.org/10.1016/j.jddst.2023.104985>
 45. Adamchuk VI, Hummel JW, Morgan MT, Upadhyaya SK. On-the-go soil sensors for precision agriculture. *Computers and electronics in agriculture*. 2004 Jul 1;44(1):71-91. <https://doi.org/10.1016/j.compag.2004.03.002>
 46. Fateh ST, Moradi L, Kohan E, Hamblin MR, Dezfali AS. Comprehensive review on ultrasound-responsive theranostic nanomaterials: mechanisms, structures and medical applications. *Beilstein Journal of Nanotechnology*. 2021 Aug 11;12(1):808-62. <https://doi.org/10.3762/bjnano.12.64>
 47. Chanchal DK, Alok S, Kumar M, Bijauliya RK, Rashi S, Gupta S. A Brief Review on *Abelmoschus esculentus* linn. okra. *International Journal of Pharmaceutical Sciences and Research*. 2018 Jan 1;9(1):58-66.
 48. Singh S, Jain SK, Alok S, Chanchal D, Rashi S, Pradesh U. A review on *Ficus religiosa*-An important medicinal plant. *Int J Life Sci Rev (IJLSR)*. 2016;2(1):1-1.
 49. Dongray A, Irchhaiya R, Chanchal D, Chaudhary S. Phytochemical and pharmacological properties of *Bauhinia acuminata*. *World journal of pharmaceutical research*. 2016;5(1):531-46.
 50. Bijauliya RK, Alok S, Kumar M, Chanchal DK, Yadav S. A comprehensive review on herbal cosmetics. *International Journal of Pharmaceutical Sciences and Research*. 2017 Dec 1;8(12):4930-49.
 51. Yang C, Daoping Z, Xiaoping X, Jing L, Chenglong Z. Magnesium oil enriched transdermal nanogel of methotrexate for improved arthritic joint mobility, repair, and reduced inflammation. *Journal of Microencapsulation*. 2020 Jan 2;37(1):77-90. <https://doi.org/10.1080/02652048.2019.1694086>
 52. Kunnumakkara AB, Hegde M, Parama D, Girisa S, Kumar A, Daimary UD, Garodia P, Yeniseti SC, Oommen OV, Aggarwal BB. Role of turmeric and curcumin in prevention and treatment of chronic diseases: Lessons learned from clinical trials. *ACS Pharmacology & Translational Science*. 2023 Mar 6;6(4):447-518. <https://doi.org/10.1021/acspsci.2c00012>
 53. Abdel-Rashid RS, Helal DA, Omar MM, El Sisi AM. Nanogel loaded with surfactant based nanovesicles for enhanced ocular delivery of acetazolamide. *International Journal of Nanomedicine*. 2019 Apr 29;2973-83. <https://doi.org/10.2147/IJN.S201891>
 54. Siddiqui B, Rehman AU, Haq IU, Ahmad NM, Ahmed N. Development, optimisation, and evaluation of nanoencapsulated diacerein emulgel for potential use in osteoarthritis. *Journal of microencapsulation*. 2020 Nov 16;37(8):595-608. <https://doi.org/10.1080/02652048.2020.1829140>
 55. Liu K, Zhang D, Wang W. Nanoparticle-based drug delivery system—a target strategy for osteoarthritis treatment. *Journal of Nanomaterials*. 2021 Oct 20;2021:1-5. <https://doi.org/10.1155/2021/4064983>
 56. Posinasetty B, Madhu C, Galgatte UC, Kommineni S, Basavaraj H, Rao BA, Narla D, Ande SN. Design and Evaluation of Polyherbal Nanogel for The Treatment of Rheumatoid Arthritis. *Journal of Advanced Zoology*. 2023 Sep 4;44. <https://doi.org/10.17762/jaz.v44is-5.1147>
 57. Gnana RPM, Devhare LD, Dharmamoorthy G, Khairnar MV, Prasidha R. Synthesis, Characterisation, Molecular Docking Studies and Biological Evaluation of Novel Benzothiazole Derivatives as EGFR Inhibitors for Anti-breast Cancer Agents. *International Journal of Pharmaceutical Quality Assurance*. 2023;14(3):475-480.
 58. Singh AP, Biswas A, Shukla A, Maiti P. Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles. *Signal transduction and targeted therapy*. 2019 Aug 30;4(1):33. <https://doi.org/10.1038/s41392-019-0068-3>
 59. Hearnden V, Sankar V, Hull K, Juras DV, Greenberg M, Kerr AR, Lockhart PB, Patton LL, Porter S, Thornhill MH. New developments and opportunities in oral mucosal drug delivery for local and systemic disease. *Advanced drug delivery reviews*. 2012 Jan 1;64(1):16-28. <https://doi.org/10.1016/j.addr.2011.02.008>
 60. Rovner ES, Wein AJ. Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review. *European urology*. 2002 Jan 1;41(1):6-14. [https://doi.org/10.1016/S0302-2838\(01\)00009-4](https://doi.org/10.1016/S0302-2838(01)00009-4)
 61. Bukkavar A, Jain AK, Chatap VK. Formulation Development and Evaluation of Freeze-dried Aviptadil injection using Mannitol as Cryoprotectant. *International Journal of Pharmaceutical Quality Assurance*. 2023;14(3):541-547.
 62. Pinelli F, Ortolà ÓF, Makvandi P, Perale G, Rossi F. In vivo drug delivery applications of nanogels: a review. *Nanomedicine*. 2020 Sep;15(27):2707-27. <https://doi.org/10.2217/nmm-2020-0274>
 63. Miroddi M, Navarra M, Quattropiani MC, Calapai F, Gangemi S, Calapai G. Systematic Review of Clinical Trials Assessing Pharmacological Properties of *Salsvia* Species on Memory, Cognitive Impairment and Alzheimer's Disease. *CNS neuroscience & therapeutics*. 2014 Jun;20(6):485-95. <https://doi.org/10.1111/cns.12270>
 64. Marijnissen AC, Van Roermund PM, Van Melkebeek J, Schenk W, Verbout AJ, Bijlsma JW, Lafeber FP. Clinical benefit of joint distraction in the treatment of severe osteoarthritis of the ankle: proof of concept in an open prospective study and in a randomized controlled study. *Arthritis & Rheumatism: Official Journal of the American College of Rheumatology*. 2002 Nov;46(11):2893-902.

- <https://doi.org/10.1002/art.10612>
65. Enteshari-Moghaddam A, Isazadehfar K, Habibzadeh A, Hemmati M. Efficacy of methotrexate on pain severity reduction and improvement of quality of life in patients with moderate to severe knee osteoarthritis. *Anesthesiology and Pain Medicine*. 2019 Jun;9(3). <https://doi.org/10.5812/2Faapm.89990>
 66. Myers WA, Gottlieb AB, Mease P. Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. *Clinics in dermatology*. 2006 Sep 1;24(5):438-47. <https://doi.org/10.1016/j.clindermatol.2006.07.006>
 67. O'Dwyer T, Monaghan A, Moran J, O'Shea F, Wilson F. Behaviour change intervention increases physical activity, spinal mobility and quality of life in adults with ankylosing spondylitis: a randomised trial. *Journal of physiotherapy*. 2017 Jan 1;63(1):30-9. <https://doi.org/10.1016/j.jphys.2016.11.009>
 68. Cronstein BN, Sunkureddi P. Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis. *JCR: Journal of Clinical Rheumatology*. 2013 Jan 1;19(1):19-29. DOI: 10.1097/RHU.0b013e31827d8790
 69. Suhail M, Rosenholm JM, Minhas MU, Badshah SF, Naeem A, Khan KU, Fahad M. Nanogels as drug-delivery systems: A comprehensive overview. *Therapeutic delivery*. 2019 Nov;10(11):697-717. <https://doi.org/10.4155/tde-2019-0010>
 70. Harun-Ur-Rashid M, Jahan I, Foyez T, Imran AB. Bio-Inspired Nanomaterials for Micro/Nanodevices: A New Era in Biomedical Applications. *Micromachines*. 2023 Sep 18;14(9):1786. <https://doi.org/10.3390/mi14091786>
 71. Li Y, Maciel D, Rodrigues J, Shi X, Tomas H. Biodegradable polymer nanogels for drug/nucleic acid delivery. *Chemical reviews*. 2015 Aug 26;115(16):8564-608. <https://doi.org/10.1021/cr500131f>
 72. Pedrosa SS, Pereira P, Correia A, Moreira S, Rocha H, Gama FM. Biocompatibility of a self-assembled crosslinkable hyaluronic acid nanogel. *Macromolecular bioscience*. 2016 Nov;16(11):1610-20. <https://doi.org/10.1002/mabi.201600221>
 73. Nochi T, Yuki Y, Takahashi H, Sawada SI, Mejima M, Kohda T, Harada N, Kong IG, Sato A, Kataoka N, Tokuhara D. Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. *Nature materials*. 2010 Jul;9(7):572-8. <https://doi.org/10.1038/nmat2784>
 74. Rashidzadeh H, Rezaei SJ, Danafar H, Ramazani A. Multifunctional pH-responsive nanogel for malaria and cancer treatment: Hitting two targets with one arrow. *Journal of Drug Delivery Science and Technology*. 2022 Oct 1;76:103740. <https://doi.org/10.1016/j.jddst.2022.103740>
 75. Panonnummal R, Sabitha M. Anti-psoriatic and toxicity evaluation of methotrexate loaded chitin nanogel in imiquimod induced mice model. *International journal of biological macromolecules*. 2018 Apr 15;110:245-58. <https://doi.org/10.1016/j.ijbiomac.2017.10.112>
 76. Han Y, Pang X, Pi G. Biomimetic and bioinspired intervention strategies for the treatment of rheumatoid arthritis. *Advanced Functional Materials*. 2021 Sep;31(38):2104640. <https://doi.org/10.1002/adfm.202104640>
 77. Aderibigbe BA, Naki T. Design and efficacy of nanogels formulations for intranasal administration. *Molecules*. 2018 May 23;23(6):1241. <https://doi.org/10.3390/molecules23061241>
 78. Sivaram AJ, Rajitha P, Maya S, Jayakumar R, Sabitha M. Nanogels for delivery, imaging and therapy. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*. 2015 Jul;7(4):509-33. <https://doi.org/10.1002/wnan.1328>
 79. Abolmaali S, Tamaddon A, Kamali-Sarvestani E, Ashraf M, Dinarvand R. Stealth nanogels of histinylated poly ethyleneimine for sustained delivery of methotrexate in collagen-induced arthritis model. *Pharmaceutical research*. 2015 Oct;32:3309-23. <https://doi.org/10.1007/s11095-015-1708-0>
 80. De Flora S, Camoirano A, Bagnasco M, Bennicelli C, Corbett GE, Kerger BD. Estimates of the chromium (VI) reducing capacity in human body compartments as a mechanism for attenuating its potential toxicity and carcinogenicity. *Carcinogenesis*. 1997 Mar 1;18(3):531-7. <https://doi.org/10.1093/carcin/18.3.531>
 81. Li T, Yang J, Weng C, Liu P, Huang Y, Meng S, Li R, Yang L, Chen C, Gong X. Intra-articular injection of anti-inflammatory peptide-loaded glycol chitosan/fucoidan nanogels to inhibit inflammation and attenuate osteoarthritis progression. *International journal of biological macromolecules*. 2021 Feb 15;170:469-78. <https://doi.org/10.1016/j.ijbiomac.2020.12.158>
 82. Opretzka LC, do Espírito-Santo RF, Nascimento OA, Abreu LS, Alves IM, Döring E, Soares MB, da Silva Vellozo E, Laufer SA, Villarreal CF. Natural chromones as potential anti-inflammatory agents: Pharmacological properties and related mechanisms. *International Immunopharmacology*. 2019 Jul 1;72:31-9. <https://doi.org/10.1016/j.intimp.2019.03.044>
 83. Vinogradov SV, Zeman AD, Batrakova EV, Kabanov AV. Polyplex Nanogel formulations for drug delivery of cytotoxic nucleoside analogs. *Journal of controlled release*. 2005 Sep 20;107(1):143-57. <https://doi.org/10.1016/j.jconrel.2005.06.002>
 84. Attama AA, Nnamani PO, Onokala OB, Ugwu AA, Onugwu AL. Nanogels as target drug delivery systems in cancer therapy: A review of the last decade. *Frontiers in Pharmacology*. 2022 Sep 8;13:874510. <https://doi.org/10.3389/fphar.2022.874510>
 85. Panonnummal R, Jayakumar R, Anjaneyan G, Sabitha M. In vivo anti-psoriatic activity, biodistribution, sub-acute and sub-chronic toxicity studies of orally administered methotrexate loaded chitin nanogel in comparison with methotrexate tablet. *International journal of biological macromolecules*. 2018 Apr 15;110:259-68. <https://doi.org/10.1016/j.ijbiomac.2018.01.036>
 86. Yao H, Wu M, Lin L, Wu Z, Bae M, Park S, Wang S, Zhang W, Gao J, Wang D, Piao Y. Design strategies for adhesive hydrogels with natural antibacterial agents as wound dressings: Status and trends. *Materials Today Bio*. 2022 Dec 1;16:100429. <https://doi.org/10.1016/j.mtbio.2022.100429>
 87. Wu CS, Wang SC, Chang IS, Lin KM. The association between dementia and long-term use of benzodiazepine in the elderly: nested case-control study using claims data. *The American journal of geriatric psychiatry*. 2009 Jul 1;17(7):614-20. <https://doi.org/10.1097/JGP.0b013e3181a65210>
 88. Qin RX, Pan JG, Lu ZH, Sun Y, Yu WL. The role and mechanism of microRNAs in infections with *Streptococcus pneumoniae*. *Authorea Preprints*. 2022 Dec 19. <https://doi.org/10.22541/au.167146510.05744185/v1>
 89. Ma Y, Song Y, Ma F, Chen G. A potential polymeric nanogel system for effective delivery of chlorogenic acid to target collagen-induced arthritis. *Journal of Inorganic and Organometallic Polymers and Materials*. 2020 Jul;30:2356-65. <https://doi.org/10.1007/s10904-019-01421-8>
 90. Domingues C, Santos A, Alvarez-Lorenzo C, Concheiro A, Jarak I, Veiga F, Barbosa I, Dourado M, Figueiras A. Where is nano today and where is it headed? A review of nanomedicine and the dilemma of nanotoxicology. *ACS nano*. 2022 Jun 22;16(7):9994-10041. <https://doi.org/10.1021/acsnano.2c00128>

91. Lea RD. Ethical considerations of biotechnologies used for performance enhancement. *JBJS*. 2009 Aug 1;91(8):2048-54. DOI: 10.2106/JBJS.I.00023
92. Gilbert F, O'Connell CD, Mladenovska T, Dodds S. Print me an organ? Ethical and regulatory issues emerging from 3D bioprinting in medicine. *Science and engineering ethics*. 2018 Feb;24:73-91. <https://doi.org/10.1007/s11948-017-9874-6>
93. Paliwal R, Kumar P, Chaurasiya A, Kenwat R, Katke S, Paliwal SR. Development of nanomedicines and nano-similars: recent advances in regulatory landscape. *Current Pharmaceutical Design*. 2022 Jan 1;28(2):165-77. <https://doi.org/10.2174/1381612827666211115170001>
94. Sinha A, Simnani FZ, Singh D, Nandi A, Choudhury A, Patel P, Jha E, Kaushik NK, Mishra YK, Panda PK, Suar M. The translational paradigm of nanobiomaterials: Biological chemistry to modern applications. *Materials today bio*. 2022 Dec 15;17:100463. <https://doi.org/10.1016/j.mtbio.2022.100463>
95. Kong X, Gao P, Wang J, Fang Y, Hwang KC. Advances of medical nanorobots for future cancer treatments. *Journal of Hematology & Oncology*. 2023 Jul 14;16(1):74. <https://doi.org/10.1186/s13045-023-01463-z>
96. Satalkar P, Elger BS, Hunziker P, Shaw D. Challenges of clinical translation in nanomedicine: A qualitative study. *Nanomedicine: Nanotechnology, Biology and Medicine*. 2016 May 1;12(4):893-900. <https://doi.org/10.1016/j.nano.2015.12.376>
97. Lucivero F. Ethical assessments of emerging technologies. Cham: Springer. 2016. <https://doi.org/10.1007/978-3-319-23282-9>
98. Gostin L. Health care information and the protection of personal privacy: ethical and legal considerations. *Annals of Internal Medicine*. 1997 Oct 15;127(8_Part_2):683-90. https://doi.org/10.7326/0003-4819-127-8_Part_2-199710151-00050
99. Vela VX, Patton EW, Sanghavi D, Wood SF, Shin P, Rosenbaum S. Rethinking Medicaid coverage and payment policy to promote high value care: the case of long-acting reversible contraception. *Women's Health Issues*. 2018 Mar 1;28(2):137-43. <https://doi.org/10.1016/j.whi.2017.10.013>
100. Min SH, Cho I, Park C, Jung W, Hwang WT, Kim M, Lee KC, Lee YJ, Lim SM, Hong BH. Terahertz (THz) imaging technology for therapeutic and diagnostic applications of cancer incorporating with radiopharmaceutical fields. *Journal of Radiopharmaceuticals and Molecular Probes*. 2019;5(2):120-8. <https://doi.org/10.22643/JRMP.2019.5.2.120>